Apheresis has been a treatment modality for many conditions. Additionally, it can be used to collect cells for use in hematopoietic progenitor cell transplantations or for further manufacturing into other cellular therapy products for the treatment of malignancy, such as chimeric antigen receptor T cells. The complexity of an apheresis operation is increased dramatically than ever before and thus, the management of this service is often challenging. In this session, key practical considerations to successfully directing an apheresis service will be discussed. Specifically, since having good access is critical to an effective and safe apheresis procedure, different access options for both inpatient and outpatient populations will be discussed and compared. Given many apheresis collection products are considered therapeutic agent and to ensure their efficacy and safety during treatments, they are highly regulated by both the FDA and other accrediting agencies. Therefore, this session will also provide a brief review of basic regulatory standards along with basic principles in equipment validation and management in the field of apheresis. Lastly, medical coding terminology and the reimbursement process in apheresis will be explained to ensure proper and successful billing and communication with third party payers.
Review basic of regulations, validation, and quality management in an apheresis service.
Discuss and compare several options for access, as well as trouble-shooting for patients undergoing apheresis procedures.
Explain medical coding terminology and examine the reimbursement process in apheresis.
Please note: Huy Pham, MD, MPH did not consent to be recorded; therefore, the on-demand presentation and handout have been modified accordingly.
MD, MPH, MSc,
Department of Laboratory Medicine, UCSF School of Medicine